Literature DB >> 33078242

Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis.

Janthima Methaneethorn1,2, Nattawut Leelakanok3.   

Abstract

AIMS AND
BACKGROUND: Population pharmacokinetics with Bayesian forecasting provides for an effective approach when individualized drug dosing, while phenobarbital is a narrow therapeutic index drug that requires therapeutic drug monitoring. To date, several population pharmacokinetic models have been developed for phenobarbital, these showing a number of significant predictors of phenobarbital clearance and volume of distribution. We have therefore conducted a systematic review to summarize how these predictors affect phenobarbital pharmacokinetics as well as their relationships with pharmacokinetic parameters.
METHOD: A systematic search for studies of phenobarbital population pharmacokinetics that were carried out in humans and that employed a nonlinear mixed-effect approaches was made using the PubMed, Scopus, CINAHL Complete, and ScienceDirect databases. The search covered the period from these databases' inception to March 2020.
RESULTS: Eighteen studies were included in this review, all of which used a one-compartment structure. The estimated phenobarbital clearance and volume of distribution ranged from 0.0034 to 0.0104 L/h/kg and 0.37 to 1.21 L/kg, respectively, with body weight, age, and concomitant antiepileptic drugs being the three most frequently identified predictors of clearance. Most models were validated through the use of an advanced internal approach.
CONCLUSION: Phenobarbital clearance may be predicted from previously developed population pharmacokinetic models and their significant covariate-parameter relationships along with Bayesian forecasting. However, when applying these models in a target population, an external evaluation of these models using the target population is warranted, and it is recommended that future research be conducted to investigate the link between population pharmacokinetics and pharmacodynamics.

Entities:  

Keywords:  Nonlinear mixed-effect; Phenobarbital; Phenobarbitone; Population pharmacokinetics; Systematic review

Year:  2020        PMID: 33078242     DOI: 10.1007/s00228-020-03011-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  46 in total

Review 1.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

2.  Clinical pharmacokinetics of phenobarbital in neonates.

Authors:  D J Touw; O Graafland; A Cranendonk; R J Vermeulen; M M van Weissenbruch
Journal:  Eur J Pharm Sci       Date:  2000-12       Impact factor: 4.384

3.  CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.

Authors:  K Mamiya; A Hadama; E Yukawa; I Ieiri; K Otsubo; H Ninomiya; N Tashiro; S Higuchi
Journal:  Eur J Clin Pharmacol       Date:  2000 Feb-Mar       Impact factor: 2.953

4.  Plasma concentrations of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia.

Authors:  A Wallin; B Jalling; L O Boréus
Journal:  J Pediatr       Date:  1974-09       Impact factor: 4.406

Review 5.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of anticonvulsants.

Authors:  E F Hvidberg; M Dam
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution.

Authors:  M J Painter; C Pippenger; C Wasterlain; M Barmada; W Pitlick; G Carter; S Abern
Journal:  Neurology       Date:  1981-09       Impact factor: 9.910

8.  Distribution of phenobarbital in serum, brain and other organs from pediatric patients.

Authors:  S Onishi; Y Ohki; Y Nishimura; S Itoh; K Isobe; A Hosoe; T Yamamoto; T Yamakawa
Journal:  Dev Pharmacol Ther       Date:  1984

Review 9.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

10.  Relative bioavailability of rectally administered phenobarbital sodium parenteral solution.

Authors:  N M Graves; G B Holmes; R L Kriel; C Jones-Saete; B Ong; D J Ehresman
Journal:  DICP       Date:  1989 Jul-Aug
View more
  4 in total

1.  Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.

Authors:  Janthima Methaneethorn; Manupat Lohitnavy; Kamonwan Onlamai; Nattawut Leelakanok
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-11-24       Impact factor: 2.441

Review 2.  What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?

Authors:  Martin Šíma; Danica Michaličková; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

3.  Effective Perturbations by Phenobarbital on INa, IK(erg), IK(M) and IK(DR) during Pulse Train Stimulation in Neuroblastoma Neuro-2a Cells.

Authors:  Po-Ming Wu; Pei-Chun Lai; Hsin-Yen Cho; Tzu-Hsien Chuang; Sheng-Nan Wu; Yi-Fang Tu
Journal:  Biomedicines       Date:  2022-08-13

Review 4.  Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Authors:  Fei Tang; Chee M Ng; Henrietta S Bada; Markos Leggas
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.